The early production of IL-1β may be advantageous according to the immunogenic anti-tumor response mediated by the innate and adaptive immune system against dying tumor cells [27]; instead, at advanced stages, an IL-1β-dependent response may contribute to tumor growth, limiting the anti-tumor efficacy of chemotherapeutic agents [8,47]. The gene discussed is IL1B; the disease is neoplasm.